医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pancreatic Cancer Action Network and CDISC Partnership Develops First Data Standards for World’s Toughest Cancer

2021年11月04日 PM09:15
このエントリーをはてなブックマークに追加


 

LOS ANGELES & AUSTIN, Texas

The Pancreatic Cancer Action Network (PanCAN) and CDISC have announced the release of a new Therapeutic Area User Guide setting the first-ever global data standards specifically for pancreatic cancer. The project was funded through a two-year grant awarded to CDISC by PanCAN and is designed to lead to greater efficiencies and data sharing among the pancreatic cancer scientific community.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005108/en/

The User Guide includes global, nonproprietary clinical metadata standards and core precision medicine-focused concepts designed for pancreatic cancer to enable global researchers to efficiently collect, organize and analyze data across studies, facilitating the development of treatments that make a difference in the lives of pancreatic cancer patients. It is intended to drive operational efficiencies, expedite the regulatory review process, enable data sharing and reduce the time it takes to bring safe and effective treatments to market.

“Through this partnership with CDISC to standardize data submissions to regulatory agencies, we are creating opportunities to streamline drug development in the pancreatic cancer space,” said Sudheer Doss, PhD, PanCAN’s Chief Business Officer. “With a disease as difficult to treat as pancreatic cancer, patients can’t afford to wait. By accelerating clinical advancements through these efficiencies, we hope to improve patient outcomes and, ultimately, increase survival.”

“We are grateful to PanCAN for partnering with CDISC to allow the development of these crucial standards,” said Rhonda Facile, VP, Partnerships and Development, CDISC. “It is our hope that the research community will swiftly adopt this Therapeutic Area User Guide to conduct more powerful and meaningful research to enable the development of treatments and therapies to treat this devastating disease.”

Two years in the making, the User Guide for pancreatic cancer is now freely available via the CDISC website. To date, CDISC has developed Therapeutic Area User Guides for over 40 disease areas.

Pancreatic cancer is currently the third leading cause of cancer-related death in the U.S., with an overall five-year survival rate of just 10 percent. In 2021 more than 60,000 Americans will be diagnosed with pancreatic cancer and approximately 48,000 will die from the disease, underscoring the scientific collaboration to develop new and better treatment options for patients.

To learn more about pancreatic cancer, please visit pancan.org.

About the Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive.

About CDISC

CDISC creates clarity in clinical research by convening a global community to develop and advance data standards of the highest quality. Required by the United States Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA) and adopted by the world’s leading research organizations, CDISC standards enable the accessibility, interoperability, and reusability of data. With the help of CDISC standards, the entire research community can maximize the value of data for more efficient and meaningful research that has invaluable impact on global health. CDISC is a 501(c)(3) global nonprofit charitable organization with administrative offices in Austin, Texas, with hundreds of employees, volunteers, and member organizations around the world. https://www.cdisc.org/

View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005108/en/

CONTACT

PanCAN Media Contact:

Jillian Scholten

Senior Public Relations Manager

Pancreatic Cancer Action Network

Direct: 310-706-3360

E-mail: jscholten@pancan.org

CDISC Media Contact:

Ann P. White

Senior Manager, Technical Communications

CDISC

512.363.5826

awhite@cdisc.org

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 《新英格兰医学杂志》发表Fazirsiran治疗α-1抗胰蛋白酶缺乏症患者的二期研究结果
  • Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to Enhance Antibody Discovery for Applications in Immuno-oncology
  • 沃博联结束战略评估,决定保留表现优异的博姿业务
  • BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
  • Work for Humankind:联想技术为偏远岛屿开启无限可能